Home›Valganciclovir

Valganciclovir

Cytomegalovirus Nucleoside Analog DNA Polymerase InhibitorDNA Polymerase Inhibitors

Route: Oral

Check Valganciclovir Interactions →
40 interactions on record⛔ Black Box Warning

Valganciclovir has 40 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 15 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Imipenem And Cilastatin, Adriamycin, Amphotericin B. Patients taking Valganciclovir should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
40
Contraindicated
1
Major
15
Moderate
16

Contraindicated (1)

Major (15)

  • Valganciclovir + Adriamycin— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
  • Valganciclovir + Amphotericin B— Risk of nephrotoxicity may be increased when coadministered with valganciclovir. Monitor renal function closely.
  • Valganciclovir + Cyclosporine— Risk of nephrotoxicity may be increased when coadministered with valganciclovir. Monitor renal function closely.
  • Valganciclovir + Dapsone— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
  • Valganciclovir + Doxorubicin— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
  • Valganciclovir + Flucytosine— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
  • Valganciclovir + Hydroxyurea— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
  • Valganciclovir + Maribavir— LIVTENCITY may antagonize the antiviral activity of valganciclovir by inhibiting human CMV pUL97 kinase, which is requir…
  • Valganciclovir + Mycophenolate Mofetil— Risk of hematological and renal toxicity may be increased. Monitor for ganciclovir and MMF toxicity.
  • Valganciclovir + Pentamidine— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
  • Valganciclovir + Sulfamethoxazole And Trimethoprim— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
  • Valganciclovir + Tacrolimus— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
  • Valganciclovir + Vinblastine— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
  • Valganciclovir + Vincristine— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
  • Valganciclovir + Zidovudine— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…

Moderate (16)

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.